List view / Grid view
The FDA grants Orphan Drug Designation to treatments for rare…
The FDA grants Orphan Drug Designation to treatments for rare diseases in R&D; here are the 10 most recent for oncologic conditions.
Novartis presented results from a pivotal Phase III trial of…
6 May 2014 | By Novartis
Novartis presented results from a pivotal Phase III trial of investigational therapy Signifor® LAR in patients with acromegaly for whom current standard of care provides inadequate disease control...
Novartis announced that early stage data on 19 investigational compounds…
4 April 2014 | By Novartis
Novartis announced that early stage data on 19 investigational compounds in its oncology pipeline will be presented at the annual meeting of the American Association of Cancer Research...
Novartis announced that a pivotal Phase III trial of Jakavi®…
7 March 2014 | By Novartis
Novartis announced that a pivotal Phase III trial of Jakavi® (ruxolitinib) compared to best available therapy has met its primary endpoint of maintaining hematocrit control...
Novartis announced that the pivotal trial of the investigational oral…
19 February 2014 | By Novartis
Novartis announced that the pivotal trial of the investigational oral compound LDE225 in advanced basal cell carcinoma met its primary endpoint of demonstrating an objective response rate among patients within six months of treatment...
Novartis announced that Hervé Hoppenot, President of Novartis Oncology, will…
12 January 2014 | By Novartis
Novartis announced that Hervé Hoppenot, President of Novartis Oncology, will leave Novartis with immediate effect...
LBH589 has potential to be the first in its class…
6 December 2013 | By Novartis
LBH589 has potential to be the first in its class of anticancer agents available to patients with multiple myeloma...
Everolimus did not show survival benefit for patients with advanced…
7 August 2013 | By Novartis
Everolimus did not show survival benefit for patients with advanced hepatocellular carcinoma (HCC) after progression on or intolerance to sorafinib...
Results from a Phase III three-year follow-up study...
16 June 2013 | By Novartis
Results from a Phase III three-year follow-up study...
Results from a pivotal Phase III trial...
2 June 2013 | By Novartis
Results from a pivotal Phase III trial...
Results of a pivotal Phase III trial...
17 May 2013 | By Novartis
Results of a pivotal Phase III trial...
First filing for LDK378 anticipated in early 2014...
15 March 2013 | By Novartis
First filing for LDK378 anticipated in early 2014...
Novartis drug Exjade® first treatment approved by FDA for chronic…
23 January 2013 | By Novartis
Novartis drug Exjade® first treatment approved by FDA for chronic iron overload in patients with non-transfusion-dependent thalassemia...
Data published today...
11 January 2013 | By Novartis
Data published today...
More than 140 presentations on key data...
28 November 2012 | By Novartis
More than 140 presentations on key data...
